Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ketone doai
Reexamination Certificate
2002-09-30
2009-10-06
Hartley, Michael G (Department: 1618)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ketone doai
C514S689000
Reexamination Certificate
active
07598294
ABSTRACT:
The present invention pertains to the use of a compounds for the manufacture of a medicament for use in the treatment of a proliferative condition, wherein the compounds have the following formula:wherein: each of RB2, RB3, RB4, and RB5is independently —H, —OH, or —OMe; each of R1and R2is independently: —H, optionally substituted C1-4alkyl, or optionally substituted C5-20aryl; RA3is —H, —OH, —OC(═O)RE, —OS(═O)2OH, or —OP(═O)(OH)2; REis: —H, optionally substituted C1-6alkyl, optionally substituted C3-20heterocyclyl, or optionally substituted C5-20aryl; or a pharmaceutically acceptable salt, solvate, amide, ester, ether, chemically protected form, or prodrug thereof. The present invention also pertains to such compounds, pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, for both diagnosis and treatment of, for example, proliferative conditions, such as cancer, and inflammatory conditions.
REFERENCES:
patent: 4279930 (1981-07-01), Hall et al.
patent: 5430062 (1995-07-01), Cushman et al.
patent: 5691373 (1997-11-01), Berryman et al.
patent: 6214886 (2001-04-01), Potter et al.
patent: 2 198 945 (1988-06-01), None
patent: 61-076433 (1986-04-01), None
patent: 02-142717 (1990-05-01), None
patent: 05-246932 (1993-09-01), None
patent: 08-188546 (1996-07-01), None
patent: WO 95/05376 (1995-02-01), None
patent: WO 97/12246 (1997-04-01), None
patent: WO 99/00114 (1999-01-01), None
patent: WO 99/40056 (1999-08-01), None
patent: WO 01/46110 (2001-06-01), None
patent: WO 01/72680 (2001-10-01), None
Anto et al. Anticancer and antioxidant activity of synthetic chalcones and related compounds. Cancer Letters 97 (1995) 33-37.
Murray, et al. Tumour-specific Expression of cytochrme P450 CYP1B1, Cancer Research vol. 57, pp. 3026-3031.
Al-Kuraya et al., Modern Pathology (2005) 18, 891-897.
Rau et al., Endocrine-Related Cancer (2005) 12 511-532.
Barrie, S.E., et al., 1989, “Inhibition of 17-hydroxylase/C17-C20 Lyase by Bifluranol and Its Analogues,”J. Steroid Biochem., vol. 33, No. 6, pp. 1191-1195.
Carmichael, J., et al., 1987, “Evaluation of a Tetrazolium-based Semiautomated Colorimetric Assay: Assessment of Chemosensitivity Testing,”Cancer Research, vol. 47, p. 936-942.
de Wet, H., et al., 2001, “Sequence Requirements of the ATP-Binding Site within the C-Terminal Nucleotide-Binding Domain of Mouse P-Glycoprotein: Structure—Activity Relationships for Flavonoid Binding,”Biochemistry, vol. 40, 10382-10391.
Ducki, S., et al., 1998, “Potent Antimitotic and Cell growth Inhibitory Properties of Substituted Chalcones,”BioMed. Chem. Lett., vol. 8, pp. 1051-1056.
Hsieh, H-K et al., 2000, “Synthesis and Anti-Inflammatory Effect of Chalcones,”Journal of Pharmacy and Pharmacology, vol. 52, No. 2, pp. 163-171.
Iwata Susumu et al., 1995, “Antitumorigenic Activities of Chalcones. I. Inhibitory Effects of Chalcone Derivatives on 32P-Incorporation into Phospholipids of HeLa Cells Promoted by 12-O-Tetradecanoyl-phorbol 13-acetate (TPA),”Biological&Pharmaceutical Bulletin(of Japan), vol. 18, No. 12, pp. 1710-1713.
Mosmann, T., 1983, “Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays,”Journal of Immunological Methods, vol. 65, pp. 55-63.
Murray, G. I., et al., 1997, “Tumour-specific Expression of Cytochrome P450 CYP1B1,”Cancer Research, vol. 57, pp. 3026-3031.
Parmar, V.S., et al., 1997, “Anti-Invasive Activity of Alkaloids and Polyphenolics in Vitro,”Bioorganic&Medicinal Chemistry, vol. 5, No. 8, pp. 1609-1619.
Pettit, G.R., et al., 1995, “Antineoplastic agents 322. Synthesis of Combretastatin A-4 Prodrugs,”Anticancer Drug Design, vol. 10, pp. 299-309.
Shibata, S., 1994, “Anti-Tumorigenic Chalcones,”Stem Cells, vol. 12, pp. 44-52.
Sogawa et al., 1993, “3,4-Dihydroxychalcones as Potent 5-Lipoxygenase and Cyclooxygenase Inhibitors,” Journal of Medicinal Chemistry, vol. 36, No. 24, pp. 3904-3909.
Spink, D.C., et al., 1994, “The Effects of 2,3,7,8-Tetrachlorodibenzo-p-dioxin on Estrogen Metabolism in MCF-7 Breast Cancer Cells: Evidence for Induction of a Novel 17β-Estradiol 4-hydroxylase,”J. Steroid Biochem. Mol. Biol., vol. 51, No. 5/6, pp. 251-258.
Sutter, T.R., et al, 1994, “Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps onto chromosome 2,”J. Biol. Chem., vol. 269, No. 18, pp. 13092-13099.
Tanaka et al., 2001, “Influence of Natural and Synthesis Compounds on Cell Surface Expression of Cell Adhesion Molecules ICAM-1 and VCAM-1,”Planta Medica, vol. 67, No. 2, pp. 108-113.
Yamashita, D.S., et al, 1994, “Design, Synthesis and Evaluation of Dual Domain FKBP Ligands,”Bioorg. Med. Chem. Lett., vol. 4, No. 2, pp. 325-328.
Butler Paul C
Potter Gerard A
Elrifi Ivor R.
Gembeh Shirley V
Hartley Michael G
Loebach Jennifer L.
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
LandOfFree
3,4-methylenedioxy-substituted chalcones as therapeutic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3,4-methylenedioxy-substituted chalcones as therapeutic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3,4-methylenedioxy-substituted chalcones as therapeutic agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4105430